183 related articles for article (PubMed ID: 37152309)
21. IL-18 as a biomarker linking systemic juvenile idiopathic arthritis and macrophage activation syndrome.
Yasin S; Fall N; Brown RA; Henderlight M; Canna SW; Girard-Guyonvarc'h C; Gabay C; Grom AA; Schulert GS
Rheumatology (Oxford); 2020 Feb; 59(2):361-366. PubMed ID: 31326996
[TBL] [Abstract][Full Text] [Related]
22. Evidence-based diagnosis and treatment of macrophage activation syndrome in systemic juvenile idiopathic arthritis.
Boom V; Anton J; Lahdenne P; Quartier P; Ravelli A; Wulffraat NM; Vastert SJ
Pediatr Rheumatol Online J; 2015 Dec; 13():55. PubMed ID: 26634252
[TBL] [Abstract][Full Text] [Related]
23. The efficacy and safety of JAK inhibitors in patients with adult-onset still's disease: A meta-analysis and systematic review.
Liao J; Tang Q; Xie X; Zhou B; Li F; Li S
Int Immunopharmacol; 2024 Jun; 137():112451. PubMed ID: 38870881
[TBL] [Abstract][Full Text] [Related]
24. Interfering with interferons: targeting the JAK-STAT pathway in complications of systemic juvenile idiopathic arthritis (SJIA).
Verweyen EL; Schulert GS
Rheumatology (Oxford); 2022 Mar; 61(3):926-935. PubMed ID: 34459891
[TBL] [Abstract][Full Text] [Related]
25. Neutrophils From Children With Systemic Juvenile Idiopathic Arthritis Exhibit Persistent Proinflammatory Activation Despite Long-Standing Clinically Inactive Disease.
Brown RA; Henderlight M; Do T; Yasin S; Grom AA; DeLay M; Thornton S; Schulert GS
Front Immunol; 2018; 9():2995. PubMed ID: 30619348
[No Abstract] [Full Text] [Related]
26. Systemic Juvenile Idiopathic Arthritis-Associated Lung Disease: Characterization and Risk Factors.
Schulert GS; Yasin S; Carey B; Chalk C; Do T; Schapiro AH; Husami A; Watts A; Brunner HI; Huggins J; Mellins ED; Morgan EM; Ting T; Trapnell BC; Wikenheiser-Brokamp KA; Towe C; Grom AA
Arthritis Rheumatol; 2019 Nov; 71(11):1943-1954. PubMed ID: 31379071
[TBL] [Abstract][Full Text] [Related]
27. Identification of the best cutoff points and clinical signs specific for early recognition of macrophage activation syndrome in active systemic juvenile idiopathic arthritis.
Kostik MM; Dubko MF; Masalova VV; Snegireva LS; Kornishina TL; Chikova IA; Likhacheva TS; Isupova EA; Glebova NI; Kuchinskaya EM; Balbotkina EV; Buchinskaya NV; Kalashnikova OV; Chasnyk VG
Semin Arthritis Rheum; 2015 Feb; 44(4):417-22. PubMed ID: 25300700
[TBL] [Abstract][Full Text] [Related]
28. A dysregulated interleukin-18-interferon-γ-CXCL9 axis impacts treatment response to canakinumab in systemic juvenile idiopathic arthritis.
Hinze T; Kessel C; Hinze CH; Seibert J; Gram H; Foell D
Rheumatology (Oxford); 2021 Nov; 60(11):5165-5174. PubMed ID: 33576397
[TBL] [Abstract][Full Text] [Related]
29. Development and initial validation of the MS score for diagnosis of macrophage activation syndrome in systemic juvenile idiopathic arthritis.
Minoia F; Bovis F; Davì S; Horne A; Fischbach M; Frosch M; Huber A; Jelusic M; Sawhney S; McCurdy DK; Silva CA; Rigante D; Unsal E; Ruperto N; Martini A; Cron RQ; Ravelli A;
Ann Rheum Dis; 2019 Oct; 78(10):1357-1362. PubMed ID: 31296501
[TBL] [Abstract][Full Text] [Related]
30. Comparative efficacy and safety of JAK inhibitors as monotherapy and in combination with methotrexate in patients with active rheumatoid arthritis: A systematic review and meta-analysis.
Liu L; Yan YD; Shi FH; Lin HW; Gu ZC; Li J
Front Immunol; 2022; 13():977265. PubMed ID: 36248913
[TBL] [Abstract][Full Text] [Related]
31. JAK inhibitor treatment for inborn errors of JAK/STAT signaling: An ESID/EBMT-IEWP retrospective study.
Fischer M; Olbrich P; Hadjadj J; Aumann V; Bakhtiar S; Barlogis V; von Bismarck P; Bloomfield M; Booth C; Buddingh EP; Cagdas D; Castelle M; Chan AY; Chandrakasan S; Chetty K; Cougoul P; Crickx E; Dara J; Deyà-Martínez A; Farmand S; Formankova R; Gennery AR; Gonzalez-Granado LI; Hagin D; Hanitsch LG; Hanzlikovà J; Hauck F; Ivorra-Cortés J; Kisand K; Kiykim A; Körholz J; Leahy TR; van Montfrans J; Nademi Z; Nelken B; Parikh S; Plado S; Ramakers J; Redlich A; Rieux-Laucat F; Rivière JG; Rodina Y; Júnior PR; Salou S; Schuetz C; Shcherbina A; Slatter MA; Touzot F; Unal E; Lankester AC; Burns S; Seppänen MRJ; Neth O; Albert MH; Ehl S; Neven B; Speckmann C
J Allergy Clin Immunol; 2024 Jan; 153(1):275-286.e18. PubMed ID: 37935260
[TBL] [Abstract][Full Text] [Related]
32. Canakinumab in systemic juvenile idiopathic arthritis: real-world data from a retrospective Italian cohort.
De Matteis A; Bracaglia C; Pires Marafon D; Piscitelli AL; Alessio M; Naddei R; Orlando F; Filocamo G; Minoia F; Ravelli A; Tibaldi J; Cimaz R; Marino A; Simonini G; Mastrolia MV; La Torre F; Tricarico I; Licciardi F; Montin D; Maggio MC; Alizzi C; Martini G; Civino A; Gallizzi R; Olivieri AN; Ardenti Morini F; Conti G; De Benedetti F; Pardeo M
Rheumatology (Oxford); 2022 Apr; 61(4):1621-1629. PubMed ID: 34343275
[TBL] [Abstract][Full Text] [Related]
33. Prognosis, complications and treatment response in systemic juvenile idiopathic arthritis patients: A single-center experience.
Barut K; Adrovic A; Sahin S; Tarcin G; Tahaoglu G; Koker O; Yildiz M; Kasapcopur O
Int J Rheum Dis; 2019 Sep; 22(9):1661-1669. PubMed ID: 31273940
[TBL] [Abstract][Full Text] [Related]
34. New frontiers in the treatment of systemic juvenile idiopathic arthritis.
Canny S; Mellins E
F1000Res; 2017; 6():971. PubMed ID: 28690841
[TBL] [Abstract][Full Text] [Related]
35. Comparison of drug retention of TNF inhibitors, other biologics and JAK inhibitors in RA patients who discontinued JAK inhibitor therapy.
Amstad A; Papagiannoulis E; Scherer A; Rubbert-Roth A; Finckh A; Mueller R; Dudler J; Möller B; Villiger PM; Schulz MMP; Kyburz D
Rheumatology (Oxford); 2022 Dec; 62(1):89-97. PubMed ID: 35579338
[TBL] [Abstract][Full Text] [Related]
36. Refractory systemic onset juvenile idiopathic arthritis: current challenges and future perspectives.
Ambler WG; Nanda K; Onel KB; Shenoi S
Ann Med; 2022 Dec; 54(1):1839-1850. PubMed ID: 35786149
[TBL] [Abstract][Full Text] [Related]
37. Safety of JAK inhibitor use in patients with rheumatoid arthritis who developed herpes zoster after receiving JAK inhibitors.
Choi W; Ahn SM; Kim YG; Lee CK; Yoo B; Hong S
Clin Rheumatol; 2022 Jun; 41(6):1659-1663. PubMed ID: 35157164
[TBL] [Abstract][Full Text] [Related]
38. Tocilizumab-induced hypofibrinogenemia in patients with systemic-onset juvenile idiopathic arthritis.
He T; Ling J; Yang J
Sci Rep; 2023 Jun; 13(1):9050. PubMed ID: 37270663
[TBL] [Abstract][Full Text] [Related]
39. Clinical experience and safety of Janus kinase inhibitors in giant cell arteritis: a retrospective case series from Sweden.
Eriksson P; Skoglund O; Hemgren C; Sjöwall C
Front Immunol; 2023; 14():1187584. PubMed ID: 37304255
[TBL] [Abstract][Full Text] [Related]
40. Comparison of Different Diagnostic Guidelines for the Diagnosis of Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: Single Centre Experience.
Jelušić M; Kronja M; Frković M; Sršen S; Huljev Frković S; Štekić Novački K
Acta Clin Croat; 2018 Jun; 57(2):307-311. PubMed ID: 30431724
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
